VAXINIA (CF33-hNIS)
Advanced Solid Tumors
Phase 1Active
Key Facts
About Imugene
Imugene is a clinical-stage biotech with a mission to develop transformative cancer medicines by leveraging a multi-platform strategy focused on immuno-oncology. Its key achievements include advancing a pipeline of seven candidates, most notably the off-the-shelf CAR-T therapy azer-cel and the oncolytic virus platform CF33, with several programs now in Phase 1/2 clinical testing. The company's strategy mitigates risk by pursuing diverse therapeutic modalities and targets, often in combination with standard of care, to address significant unmet needs in oncology. It operates with a capital-efficient model, supported by a world-class scientific advisory board and strategic collaborations.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |